Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials

59 clinical trials for Metabolic Dysfunction-Associated Steatohepatitis across international registries, including 27 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — RECRUITING · PHASE3
• LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — RECRUITING · PHASE3
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1) — RECRUITING · PHASE3
• A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — RECRUITING · PHASE2
• A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) — RECRUITING · PHASE3
• A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) — RECRUITING · PHASE3
• A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH — RECRUITING · PHASE1
• Fibrosis Lessens After Metabolic Surgery — RECRUITING · PHASE4
• A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — RECRUITING · PHASE1
• A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — RECRUITING · PHASE2
• A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — RECRUITING · PHASE2
• A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People and Patients With Metabolic Dysfunction-associated Steatohepatitis (MASH) — RECRUITING · PHASE1
• Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial — RECRUITING · NA
• Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD — RECRUITING · NA
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH KNOWN OR SUSPECTED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-2) — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA IN PARTICIPANTS WITH BIOPSY-CONFIRMED F2- OR F3-STAGE METABOLIC DYSFUNCTION-ASSOCIATED BOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) (ZENITH-1) — RECRUITING · PHASE3
• A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change — RECRUITING
• ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants — RECRUITING · PHASE1
• Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA — RECRUITING
• A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) — RECRUITING · PHASE2
• A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) — RECRUITING · PHASE2
• Patients' Perspectives on Metabolic Dysfunction-associated Steatohepatitis: a Qualitative Study — RECRUITING
• Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH — RECRUITING
• A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) — RECRUITING · PHASE3
• A PHASE 2A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EFINOPEGDUTIDE (MK-6024) IN ADULTS WITH COMPENSATED CIRRHOSIS SECONDARY TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS — RECRUITING · PHASE2
• A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGOZAFERMIN IN SUBJECTS WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS — RECRUITING · PHASE3
• Isocaloric Navy-Bean Substitution in Adults With MASLD — NOT_YET_RECRUITING · NA
• Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease — NOT_YET_RECRUITING · NA
• A Study of CS060380 Tablets in Patients With MASH and Obesity — ACTIVE_NOT_RECRUITING · PHASE2
• Evaluation of Miricorilant on Liver Fat in Patients With MASLD — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of VV-14303 for the Treatment of Metabolic Dysfunction-associated Steatohepatitis (MASH) — NOT_YET_RECRUITING · PHASE1
• A PHASE 3, TWO-PART, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA INJECTION IN ADULT PARTICIPANTS WITH COMPENSATED CIRRHOSIS (STAGE F4 FIBROSIS) DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (NEBULA-2) — NOT_YET_RECRUITING · PHASE3
• Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) — NOT_YET_RECRUITING · PHASE2
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, 2-ARM STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF EFIMOSFERMIN ALFA INJECTION IN ADULT PARTICIPANTS WITH COMPENSATED CIRRHOSIS DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (NEBULA-1) — NOT_YET_RECRUITING · PHASE3
• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALN-CIDEB IN ADULTS WITH FIBROTIC METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) — NOT_YET_RECRUITING · PHASE2
• Nutrition Intervention Combined With Resmetirom for MASH — NOT_YET_RECRUITING · PHASE4
• A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — COMPLETED · PHASE1
• A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis — NOT_YET_RECRUITING · PHASE2
• Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) — NOT_YET_RECRUITING · PHASE2
• To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) — NOT_YET_RECRUITING · PHASE2
• A study to test how well different doses of BI 3804379 are tolerated by healthy people and patients with MASH — TERMINATED · PHASE1
• A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) — ACTIVE_NOT_RECRUITING · PHASE2
• Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) — TERMINATED · PHASE2
• A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH — COMPLETED · PHASE2
• Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) — NOT_YET_RECRUITING · PHASE1
• A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population — COMPLETED
• A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis — OTHER · PHASE2
• Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults — NOT_YET_RECRUITING · PHASE1

Refine this search